Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.
Adult
Aniline Compounds
/ pharmacology
Animals
Antibodies, Monoclonal, Humanized
/ pharmacology
Antibody-Dependent Cell Cytotoxicity
/ drug effects
Apoptosis
B-Cell Activation Factor Receptor
/ antagonists & inhibitors
Cell Proliferation
Drug Resistance, Neoplasm
/ drug effects
Drug Therapy, Combination
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Killer Cells, Natural
/ drug effects
Male
Mice
Mice, Inbred NOD
Mice, SCID
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Prognosis
Receptor, Transforming Growth Factor-beta Type I
/ antagonists & inhibitors
Triazoles
/ pharmacology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
24
01
2019
revised:
05
03
2019
accepted:
21
05
2019
pubmed:
30
5
2019
medline:
10
9
2020
entrez:
30
5
2019
Statut:
ppublish
Résumé
Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating factor receptor (BAFF-R) on the surface of drug-resistant B-ALL cells as a therapeutic target. We used anti-BAFF-R (VAY736), optimized for natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), to kill drug-resistant ALL cells. VAY736 antibody and NK cell treatments significantly decreased ALL disease burden and provided survival benefit
Identifiants
pubmed: 31138521
pii: 2326-6066.CIR-19-0058
doi: 10.1158/2326-6066.CIR-19-0058
pmc: PMC6606383
mid: NIHMS1530403
doi:
Substances chimiques
Aniline Compounds
0
Antibodies, Monoclonal, Humanized
0
B-Cell Activation Factor Receptor
0
TNFRSF13C protein, human
0
Triazoles
0
vactosertib
6T4O391P5Y
Receptor, Transforming Growth Factor-beta Type I
EC 2.7.11.30
TGFBR1 protein, human
EC 2.7.11.30
ianalumab
ZN2GQ3II96
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1106-1119Subventions
Organisme : NCI NIH HHS
ID : R21 CA201775
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002549
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Blood. 2001 Sep 1;98(5):1326-31
pubmed: 11520778
Annu Rev Immunol. 2003;21:231-64
pubmed: 12427767
N Engl J Med. 2004 Apr 8;350(15):1535-48
pubmed: 15071128
Exp Hematol. 2005 Mar;33(3):344-52
pubmed: 15730858
Hum Pathol. 2005 Oct;36(10):1113-9
pubmed: 16226112
Cancer Res. 2005 Nov 1;65(21):10050-8
pubmed: 16267031
N Engl J Med. 2006 Jan 12;354(2):166-78
pubmed: 16407512
Semin Immunol. 2006 Oct;18(5):263-75
pubmed: 16914324
J Exp Med. 2006 Oct 30;203(11):2551-62
pubmed: 17060474
Mol Cancer Ther. 2007 Feb;6(2):460-70
pubmed: 17267661
Blood. 2008 Jun 15;111(12):5486-95
pubmed: 18390837
J Immunol. 2008 Sep 15;181(6):3784-92
pubmed: 18768831
Acta Haematol. 2009;121(1):27-31
pubmed: 19332983
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13945-50
pubmed: 19666484
Drug Des Devel Ther. 2009 Sep 21;3:7-16
pubmed: 19920917
Neuro Oncol. 2010 Jan;12(1):7-13
pubmed: 20150362
J Clin Oncol. 2010 May 20;28(15):2529-37
pubmed: 20406941
Cancer Res. 2010 Jun 1;70(11):4346-56
pubmed: 20460528
Cell Cycle. 2010 Dec 15;9(24):4884-92
pubmed: 21099364
N Biotechnol. 2011 Sep;28(5):518-29
pubmed: 21473941
PLoS One. 2012;7(1):e30264
pubmed: 22279576
Leukemia. 2012 Aug;26(8):1786-96
pubmed: 22373785
Clin Dev Immunol. 2012;2012:421702
pubmed: 22899948
Clin Cancer Res. 2013 Apr 15;19(8):2132-43
pubmed: 23378384
Curr Hematol Malig Rep. 2013 Jun;8(2):123-31
pubmed: 23539383
Curr Opin Oncol. 2013 Dec;25 Suppl 3:S1-13; quiz S14-6
pubmed: 24305505
Front Immunol. 2014 Jan 06;4:509
pubmed: 24432023
Leukemia. 2014 Dec;28(12):2336-43
pubmed: 24781017
Mol Cancer Ther. 2014 Jul;13(7):1704-16
pubmed: 24817629
Mol Cancer Ther. 2014 Jun;13(6):1567-77
pubmed: 24825858
Clin Cancer Res. 2014 Dec 1;20(23):5986-94
pubmed: 25281696
Biochim Biophys Acta. 2016 Mar;1863(3):414-426
pubmed: 26255027
Drug Des Devel Ther. 2015 Aug 10;9:4479-99
pubmed: 26309397
Biochim Biophys Acta. 2016 Mar;1863(3):449-463
pubmed: 26334291
Cancer Sci. 2016 Feb;107(2):140-8
pubmed: 26583567
Leukemia. 2016 Apr;30(4):800-11
pubmed: 26621337
Sci Signal. 2016 Feb 16;9(415):ra19
pubmed: 26884601
J Pediatr Hematol Oncol. 2016 Apr;38(3):167-72
pubmed: 26950089
Nat Immunol. 2016 Aug 19;17(9):1025-36
pubmed: 27540992
N Engl J Med. 2016 Sep 15;375(11):1044-53
pubmed: 27626518
Sci Rep. 2016 Sep 27;6:34310
pubmed: 27670158
Blood. 2017 Oct 19;130(16):1832-1844
pubmed: 28790105
Blood Cancer J. 2017 Dec 20;7(12):659
pubmed: 29259173
Br J Haematol. 1985 Jan;59(1):45-53
pubmed: 3855649
Cell. 1994 Feb 11;76(3):519-29
pubmed: 8313472